Forte Biosciences (FBRX)
(Delayed Data from NSDQ)
$5.84 USD
+0.26 (4.66%)
Updated Nov 15, 2024 03:30 PM ET
After-Market: $5.83 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 3/17/25 |
---|---|
Current Quarter | -5.75 |
EPS Last Quarter | -4.54 |
Last EPS Surprise | 32.74% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -22.50 |
Next Year | -18.25 |
EPS (TTM) | -16.29 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (12/2024) |
Next Qtr (3/2025) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (12/2024) |
Next Qtr (3/2025) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -5.75 | NA | -22.50 | -18.25 |
# of Estimates | 1 | NA | 2 | 2 |
Most Recent Consensus | -5.75 | NA | -21.75 | -15.25 |
High Estimate | -5.75 | NA | -21.75 | -15.25 |
Low Estimate | -5.75 | NA | -23.25 | -21.25 |
Year ago EPS | -1.00 | -4.00 | -25.00 | -22.50 |
Year over Year Growth Est. | -475.00% | NA | 10.00% | 18.89% |
Agreement - Estimate Revisions
Current Qtr (12/2024) |
Next Qtr (3/2025) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | NA | 0 | 0 |
Up Last 30 Days | 0 | NA | 0 | 0 |
Up Last 60 Days | 0 | NA | 0 | 0 |
Down Last 7 Days | 0 | NA | 0 | 0 |
Down Last 30 Days | 0 | NA | 0 | 0 |
Down Last 60 Days | 0 | NA | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (12/2024) |
Next Qtr (3/2025) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -5.75 | NA | -22.50 | -18.25 |
7 Days Ago | -5.75 | NA | -22.50 | -18.25 |
30 Days Ago | -5.75 | NA | -22.50 | -18.25 |
60 Days Ago | -5.75 | NA | -22.50 | -18.25 |
90 Days Ago | -5.75 | NA | -18.83 | -13.50 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (12/2024) |
Next Qtr (3/2025) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -5.75 | NA | -22.50 | -18.25 |
Zacks Consensus Estimate | -5.75 | NA | -22.50 | -18.25 |
Earnings ESP | 0.00% | NA | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (9/2024) |
Quarter Ending (6/2024) |
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -4.54 | -6.75 | -4.00 | -1.00 | NA |
Estimate | -6.75 | -4.00 | NA | NA | NA |
Difference | 2.21 | -2.75 | NA | NA | -0.27 |
Surprise | 32.74% | -68.75% | NA | NA | -18.01% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more